Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX

BACKGROUND: Korean National Health Insurance reimburses factor VIII (FVIII) and factor IX (FIX) clotting factor concentrate (CFC) infusions to discrepant activity levels, allowing elevation of FVIII activity to 60 IU/dL and FIX to 40 IU/dL. We aimed to assess hemostatic response to these target leve...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Res
Auteurs principaux: Yoo, Ki-Young, Jung, Soo-Young, Hwang, Sung-Ho, Lee, Su-Min, Park, Jong-Ho, Nam, Hyun-Ja
Format: Artigo
Langue:Inglês
Publié: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2018
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5898993/
https://ncbi.nlm.nih.gov/pubmed/29662861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5045/br.2018.53.1.41
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires